Get startedLog in
    Picture of Curative Biotechnology logo

    CUBT — Curative Biotechnology Income Statement

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro Cap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Curative Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

    2019
    December 31st
    2020
    December 31st
    2021
    December 31st
    Period Length:12 M12 M12 M
    Source:PROSPECTUSPROSPECTUSPROSPECTUS
    Standards:
    USG
    USG
    USG
    Status:FinalFinalFinal
    Revenue
    Total Revenue000
    Cost of Revenue
    Gross Profit000
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Unusual Expense / Income
    Total Operating Expenses-0.2234.645.16
    Operating Profit0.223-4.64-5.16
    Total Net Non Operating Interest Income / Expense
    Net Income Before Taxes0.207-4.67-5.34
    Net Income After Taxes0.207-4.67-5.34
    Net Income Before Extraordinary Items
    Net Income0.207-4.67-5.34
    Adjustments to Net Income
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income0.207-4.67-18.8
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-0-0.008-0.033